Peptide Therapy, considered.
Peptides are not a single thing. BPC-157, sermorelin, ipamorelin, CJC-1295, GHK-Cu, and tirzepatide are all peptides — and all have different evidence bases, regulatory standings, and clinical uses. The category requires more discrimination than its marketing usually allows.
Three categories worth distinguishing.
Approved drugs that are technically peptides: tirzepatide, semaglutide, glucagon, calcitonin, oxytocin. These have full FDA approval and conventional regulatory status.
Compounded peptides used in clinical practice: sermorelin, ipamorelin, CJC-1295, BPC-157, TB-500, GHK-Cu. These are produced by 503A/503B compounding pharmacies for specific patient prescriptions. Regulatory standing tightened in 2023–2024 — some have been moved to the FDA's restricted list.
Research chemicals sold direct-to-consumer as 'not for human use': melanotan II, MOTS-c, epitalon, and others. These are unregulated, unverified, and outside any clinical framework.
What growth-hormone peptides do.
Sermorelin, ipamorelin, and CJC-1295 stimulate the pituitary to release growth hormone in pulsatile fashion — closer to natural physiology than direct rHGH injection. Outcomes: improved sleep quality, body composition, recovery, skin quality. Modest effects on a months-long timescale.
These are not anabolic-steroid analogues and do not produce dramatic muscle gain. They are also not approved or recommended for cosmetic anti-aging. The legitimate use is in patients with documented adult growth hormone deficiency or specific clinical contexts where pulsatile GH augmentation is therapeutically indicated.
What BPC-157 and TB-500 are used for.
BPC-157 (a fragment of a gastric protein) is used clinically and athletically for connective tissue healing, gut inflammation, and tendon/ligament recovery. TB-500 (Thymosin Beta-4 fragment) for similar purposes. Animal data is robust; human RCTs are limited.
Both are popular in performance/longevity practice and have moved through varying FDA/state regulatory positions. As of 2025, BPC-157 has restricted access in many states. Source carefully — research-grade product from the open market is a different category from clinic-prescribed compounded product.
How to evaluate a peptide protocol.
Three questions: What molecule, exactly, and what is its evidence base? Where is it sourced from — a licensed compounding pharmacy or an unregulated source? What is the specific clinical goal, and how will it be measured?
A clinician who answers all three with specifics is operating in legitimate territory. A protocol that bundles five peptides with vague longevity claims and cannot articulate evidence per molecule is selling a story.
Common questions.
Are peptides legal?
FDA-approved peptide drugs are legal and prescription-only. Compounded peptides are legal when prescribed by a clinician and dispensed by a 503A/503B pharmacy for an individual patient. Research-chemical peptides sold without prescription are in a gray zone and increasingly restricted.
Will GH peptides help me build muscle?
Modestly, over months, in conjunction with training and adequate nutrition. They are not anabolic steroids. Expect subtle improvements in body composition, not dramatic ones.
How does sermorelin compare to direct HGH?
Sermorelin stimulates endogenous pulsatile GH release, preserving natural feedback. Direct rHGH suppresses pituitary function and produces continuous (rather than pulsatile) elevation. Sermorelin is generally regarded as the more conservative protocol.
Are there side effects?
Injection-site reactions, water retention, occasional joint discomfort. Most resolve with dose adjustment. GH peptides should not be used in active malignancy.
Why are some peptides hard to get now?
Several previously available compounded peptides (BPC-157, TB-500, others) have been moved to the FDA's negative compounding list or face state-level restrictions. Access depends heavily on state and clinic. Reputable practices update their offerings as regulatory positions shift.